Atlas Trials

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Clinical trial NCT03844945 · COMPLETED

Trial details

NCT number
NCT03844945
Sponsor
Aerie Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Open Angle GlaucomaOcular Hypertension
Start date
2019-03-19
Primary completion
2019-09-19
Enrollment
215

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.